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Interendothelial cell tight junctions (TJs) proteins contribute to maintain the structural and
functional integrity of the blood–brain barrier (BBB) and several efﬂux transporters regulate
transport of compounds acrossBBB.A unique double compartment-model of theBBB, con-
sisting of cerebral endothelial cells isolated from cryopreserved human glial tumors, alone
and in the presence of human astroglial cells derived from the same tissue preparation
was established. Endothelial cell viability and transendothelial electrical resistance (TEER)
were measured in this model and three representative TJ proteins – occludin (OCLN),
zonula occludens-1 (ZO-1) and claudin-5 (CLN-5) – as well as several drug efﬂux trans-
porters – P-glycoprotein (P-gp), multidrug resistance protein-1 and 2 (MRP-1 and MRP-2),
organic anion-transporting polypeptide-1 and 3 (oatp1 and oatp3) were analyzed at both the
protein and gene transcript level. Functional activity of P-gp and MRP-1 was also assessed.
Endothelial cell viability as well asTEER signiﬁcantly increased in the presence of glial cells.
A signiﬁcant increase of expression of OCLN, ZO-1, and CLN-5 proteins aswell as of several
drug transporter proteins except oatp3 and MRP-1, was also found in the presence of glial
cells. All the gene transcripts protein analyzed were found to be signiﬁcantly increased in
the presence of glial cells. A suitable functional activity of P-gp and MRP-1 was also found.
These results demonstrate that this brain endothelium culture system mimics a physio-
logically relevant situation and may therefore provide a new tool for studying the effects
of biological ﬂuids such as serum and cerebrospinal ﬂuid from patients with neurological
disorders underlying a BBB alteration in disease pathogenesis.
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INTRODUCTION
The blood–brain barrier (BBB) is a specialized system, consisting
of brain microvascular endothelial cells and astroglial cell endfeet,
that protects the brain from potentially toxic substances and regu-
lates the passage of circulating molecules on the basis of their size
and physical–chemical characteristics, regulated by selective trans-
porters thus contributing to themaintenance of brain parenchyma
homeostasis. The structural and functional integrity of the BBB
is maintained by interendothelial cell tight junctions (TJs), which
are characterized by several integral proteins including claudins
and occludin, linked to the actin cytoskeleton by other scaffolding
proteins such as zonula occludens (ZO;Ballabh et al., 2004). Trans-
port across the BBB also depends on several efﬂux transporters
expressed by brain endothelial cells, including P-glycoprotein
(P-gp; Cordon-Cardo et al., 1989), organic anion-transporting
polypeptide (oatp; Gao et al., 1999) and multidrug resistance pro-
teins (MRPs; Culot et al., 2008). These efﬂux proteins actively
pump compounds out of the endothelial cells and back into the
blood (De Lange, 2004), reducing the exposure of the central ner-
vous system (CNS) to delivered drugs. These barrier properties are
mostly induced and maintained by the close association between
astrocytic foot processes and the brain capillary endothelial cells
(Bradbury, 1985, 1993; Goldstein and Betz, 1986). Several in vitro
models have been developed over the last two decades to study the
physiology, pharmacology and pathophysiology of the BBB. Most
of these models were based on the use of primary endothelial
cell cultures prepared with brain capillaries, umbilical veins and
aorta isolated from human, porcine, bovine, rodent, and murine
species (Biegel et al., 1995; Teifel and Friedl, 1996; Cecchelli et al.,
1999; Abbott, 2000). Due to the known role of astrocytes in induc-
ing and maintaining BBB properties and integrity in the brain
endothelium (Arthur et al., 1987; Janzer and Raff, 1987), endothe-
lial cells have been co-cultured with primary rat astrocytes as well
as rat or human glial tumor cell lines, cell-conditioned media or
pericytes (Dehouk et al., 1990; Meyer et al., 1990, 1991; Rubin
et al., 1991; Perrière et al., 2007). However, there are also a few
in vitro BBB models based on commercially available primary
humanbrain endotheliumcultures or on immortalizedhumancell
lines in the presence or absence of human astroglial cells (Megard
et al., 2002; Weksler et al., 2005). BBB alterations have been found
to play a role in the pathogenesis of several human neurologi-
cal diseases, including multiple sclerosis (Kermode et al., 1990)
and HIV-related neurological disorders (Smith et al., 1990), while
changes in the endothelial cell basement membrane have been
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demonstrated in autopsy brains from patients with Alzheimer’s
disease (Kalback et al., 2004). An in vitro BBB model capable
of reproducing most of the characteristics of the adult human
BBB and overcoming possible species differences mainly related to
endothelial surface receptors could therefore represent a valid tool
for the study of BBB alterations inCNSpathologies. To address this
issue, we established a unique double compartment-model of the
BBB, consisting of cerebral endothelial cells isolated from cryop-
reserved human primary brain tumors, alone and in the presence
of human astroglial cells derived from the same tissue prepara-
tion. In this model, we measured endothelial cell viability and
transendothelial electrical resistance (TEER) and analyzed three
representative TJ proteins – occludin (OCLN), zonula occludens-
1 (ZO-1), and claudin-5 (CLN-5) as well as several drug efﬂux
transporters (P-gp, MRP-1, MRP-2, oatp1, and oatp3) at both the
protein and gene transcript level. Part of this study was presented
at the 19th Meeting of the European Neurological Society and
published elsewhere as abstract (Cioni et al., 2009).
MATERIALS AND METHODS
HUMAN BRAIN ENDOTHELIAL CELL CULTURES
Human cerebral endothelial cells were isolated from glioma speci-
mens obtained during neurosurgical operations, and preserved in
liquid nitrogen in cryopreservation medium (DMEM-20% FCS-
8% DMSO) until use, as previously described (Brunet et al., 2003).
All patients gave their informed consent according to the rules
approved by the Ethics Committee of the University of Siena. For
this work, specimens from three different tumors were used. A list
of the tumor characteristics is shown in Table 1.
Prior to cryopreservation, the meninges were removed and the
tissue was rinsed three times in DMEM to remove blood. After
thawing in a water bath at 37˚C for less than 1 min, brain tissue
was minced into small pieces, rinsed several times in DMEM and
then homogenized in Ringer’s solution: 10 mM Hepes pH 7.4. The
microvessel fraction was obtained using a previously described
technique (Mrsulja et al., 1976) and microvessel samples were
pooled in Hank’s solution at pH 7.4 and then centrifuged. The
cells were dissociated with 0.1% trypsin in Hank’s solution pH
7.4 for 15 min at 37˚C and digested for 2 h at 37˚C with collage-
nase/dispase (2 mg/ml) and DNase (10μg/ml) in DMEM. After
blocking digestion by feeding medium, the cells were resuspended
in 5 ml of DMEM-20% FCS, placed in a Petri dish and incubated
in an atmosphere of air with 5% CO2 at 37˚C. After 2 days, the
feed solution was removed and centrifuged, then the pellet was
resuspended in 5 ml of feed medium and seeded again in a Petri
Table 1 | Clinical and histological characteristics of the glial tumors
used in the study.
Sex and
age (years)
Tumor type Histological grade Localization
M 68 Astrocytoma Grade II Right frontal lobe
F 59 Glioblastoma Grade IV Left temporal lobe
F 61 Astrocytoma Grade IV Right frontal lobe
M, male subject; F, female subject.
dish. The cells grew slowly as sheets and/or networks of elon-
gated cells, covering the entire surface of the dish in 3–4 weeks.
In all the cultures, 98–99% of the cells were positive for Factor
VIII, a reliable marker of endothelial cells, which was detected
as previously described (Annunziata et al., 1995). No cells posi-
tive for glial ﬁbrillary acidic protein (GFAP), a reliable marker of
astroglial cells, were detected as below described, indicating the
absence of residual glioma cells. When they reached conﬂuence,
the cells were trypsinized in 0.1% trypsin in Hank’s solution at pH
7.4 for 15 min at 37˚C, counted (for each 35 mm Petri dish, nearly
2× 106 cells were yielded) and seeded in 96-well microplates
(Nunc, Denmark) or in multi-well inserts (Nunc) at a density
of 2× 104 cells/well or insert, in a feed medium consisting of 20%
heat-inactivated FCS, 5 mg/ml peptone, 25% glucose, 1% vita-
mins, 1% amino acids, 1% antibiotic–antimycotic solution, and
2 mM l-Glutamine in DMEM (all from Sigma, St. Louis, USA).
The culture viability was tested at 1, 7, and 14 days in vitro (DIV)
using a MTT assay as previously described (Annunziata et al.,
1998), and TEER was tested at the same times. The highest via-
bility and TEER values were found at 7 DIV and remained stable
until 14 DIV (data not shown); 7 DIV was therefore chosen as
the cell stage time-point for all assays. A representative conﬂuent
monolayer of human brain endothelial cell culture is shown in
Figure 1.
TRANSENDOTHELIAL ELECTRICAL RESISTANCE MEASUREMENT
Primary human brain endothelial cells were seeded on multi-well
inserts (0.2μm pore size) for 96-well microplates (Nunc). Resis-
tance was measured using an assembly containing current-passing
and voltage-measuring electrodes (World Precision Instruments
Inc., Sarasota, FL, USA) according to the manufacturer’s instruc-
tions. The ﬁnal resistance (Ω cm2) was calculated as unit area
resistance obtained by multiplying the meter readings by the effec-
tive surface area of the ﬁlter membrane. The value of blank ﬁlters
was subtracted from that of ﬁlters with cells.
HUMAN ASTROGLIAL CULTURES
The astrocyte fraction was obtained from the same tumor pool as
the cerebral endothelial cells. The astrocytes were isolated from
the middle fraction, obtained by density gradient centrifuga-
tion, according to the technique used for microvessel isolation
(Mrsulja et al., 1976). The fraction was rinsed three times with
FIGURE 1 | Phase contrast image of a representative confluent
monolayer of human brain endothelial culture at 30days in vitro (DIV)
prepared from glioblastoma listed inTable 1. Scale bar=200μm.
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complete feed medium consisting of 20% heat-inactivated FCS,
5 mg/ml peptone, 25% glucose, 1% vitamins, 1% amino acids,
1% antibiotic–antimycotic solution, and 2 mM l-Glutamine in
DMEM. The pellet was then resuspended in the same medium
in a Petri dish and incubated in an atmosphere of air with 5%
CO2 at 37˚C. The cells grew quickly, covering the entire surface of
the dish in 1 week. When they reached conﬂuence the cells were
trypsinizedwith 0.1% trypsin inHank’s solution at pH7.4 (15 min
at 37˚C), then counted and seeded in 96-well microplates (Nunc)
at a density of 2× 104 cells/well in the same feed medium as the
cerebral endothelial cultures. In all the cultures, 99% of the cells
were found to be positive for GFAP using an immunoﬂuorescence
assay with anti-GFAP monoclonal antibody (Exbio, Prague) and
FITC-conjugated goat anti-mouse IgG (Calbiochem). No Factor
VIII-positive cells were detected, indicating absence of endothe-
lial cells. The cell viability was tested at 7 DIV with a previously
described MTT assay (Annunziata et al., 1998).
CO-CULTURES OF HUMAN BRAIN ENDOTHELIAL CELLS AND GLIOMA
CELLS
For co-cultures, 2× 104 brain endothelial cells in the complete
DMEM medium reported above were seeded in tissue culture
inserts (Nunc, Denmark) for 96-well microplates (Nunc) and
2× 104 glial cells were seeded in the corresponding bottom well in
the same medium. In some control experiments, endothelial cells
were cultured alone in 96-well microplates.
CELLULAR ELISA OF TIGHT JUNCTION AND DRUG EFFLUX PROTEINS
After washing with 1% BSA in PBS at pH 7.4 and ﬁxing for 20 min
at room temperature with 4% paraformaldehyde in PBS at pH 7.4,
the endothelial cell cultures were washed again and overlaid with
3% H2O2 in methanol for 30 min to block endogenous peroxi-
dase, followed by 20% normal mouse, goat, or rabbit sera (Dako)
to block unspeciﬁc immunoglobulin binding. The cell cultures
were incubated for 2 h at room temperature with either poly-
clonal goat anti-ZO-1 antibody (4μg/ml, Santa Cruz), peroxidase
conjugated monoclonal mouse anti-occludin antibody (1μg/ml,
Zymed), monoclonal mouse anti-P-gp (2μg/ml, Alexis), mono-
clonal mouse anti-MRP-1 (10μg/ml), or anti-MRP-2 (10 μg/ml;
Alexis), polyclonal rabbit anti-oatp1 or oatp3 (1 μg/ml, Chemi-
con). As controls, after washing cell cultures were also incubated
with the corresponding antibody isotypes (all from Ancell) at the
same concentration and for the same time as the primary antibody.
After washing, afﬁnity puriﬁed peroxidase conjugated anti-goat,
mouse or rabbit IgG (all from Calbiochem) were added to the cells
as a secondary antibody for 2 h at room temperature.Afterwashing
several times, 0.1% o-phenylenediamine in 0.05 M citrate buffer at
pH 4.5 – 0.002% H2O2 was added for 10 min at room temperature
in the dark. The color reaction was stopped with 1 M H2SO4 and
measured with a photometer at 490 nm wavelength. In all assays,
the absorbance values of the IgG isotypes were subtracted from
those of the speciﬁc primary antibodies.
RT-PCR ASSAY
Total RNA was isolated from human cerebral endothelial cells
alone (2.5× 105) and in co-culture with glial cells using a column-
basedmethod (RNeasymini kit,QiagenGmbH,Hilden,Germany)
according to the manufacturer’s instructions. One hundred ng of
total RNA,measured using a NanoDrop 10000 spectrophotometer
(Thermo Fisher Scientiﬁc), were retrotranscripted and 2μl of the
cDNA library was used for each PCR. The speciﬁc primer pairs
used in the PCR are shown in Table 2.
The housekeeping gene β-actin was ampliﬁed simultaneously
in order to normalize the mRNA values.
Total RNA with 1μl of Oligo dT (Sigma, St. Louis, USA) was
denatured at 70˚C for 10 min, then reverse transcription reagents
were added. The RT reaction mixture contained dNTPs mixes
(0.5μM each), 1 U/μl RNase inhibitor (Sigma), 1× eAMV buffer,
1 U/μl eAMV reverse transcriptase (Sigma) and water, in a ﬁnal
volume of 20μl. The RT reaction was performed at 42˚C for 1 h
and inactivated by incubating the mixture at 75˚C for 2 min. Two
microliters of the cDNA library was subjected to PCR in a Minicy-
cler thermal cycler (MJ Research, Waltham, MA, USA). The PCR
reaction mixture contained 0.2 mM dNTPs mix, 0.25 μM of each
Table 2 | Primers used in RT-PCR analysis.
Primer forward (5′ →3′) Primer reverse (5′ →3′) Product size (bp)
TIGHT JUNCTION PROTEINS
OCLN AAGCAAGTGAAGGGATCTGC GGGGTTATGGTCCAAAGTCA 204
ZO-1 (a,b) CATAGAATAGACTCCCCTGG GCTTGAGGACTCGTATCTGTCC 474–234
CLN-5 ATGTCGTGCGTGGTGCAGAG GGTGCAGACCCAGGCGCCGCA 413
DRUGTRANSPORTERS
oatp1 GCCATGCCACTGCAGGGAAATG TTCTGGTACACCAAGCAGGAGCCC 292
oatp3 GCTGAGAACGCAACCGTGGTTCC GACTTGAGTTCAGGGCTGACTGTCC 164
MRP-1 ATGTCACGTGGAATACCAGC GAAGACTGAACTCCCTTCCT 349
MRP-2 ACAGAGGCTGGTGGCAACC ACCATTACCTTGTCACTGTCCATGA 227
P-gp AAGGCCTAATGCCGAACACA TTTGCCATCAAGCAGCACTTT 227
HOUSEKEEPING GENE
β-actin TCGTGATGGACTCCGGTGAC CGCCAGACAGCACTGTGTTG 452
OCLN, occludin; ZO-1, zonula occludens; CLN-5, claudin-5; oatp1, organic anion-transporting polypeptide-1; oatp3, organic anion-transporting polypeptide-3; MRP-1,
multidrug resistance protein-1; MRP-2, multidrug resistance protein-2; P-gp, P-glycoprotein.
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primer, 1× PCR buffer, 0.05 U/μl Jump Start REDTaq DNA poly-
merase (Sigma) and water, in a ﬁnal volume of 50μl. For occludin,
MRP-1, P-gp, oatp1, and oatp3, ampliﬁcation started with DNA
denaturation at 95˚C for 2 min, followed by 45 cycles at 95˚C for
1 min, 55˚C for 30 s, 72˚C for 1 min, and was stopped with a ﬁnal
extension step at 72˚C for 5 min.
For ZO-1 and MRP-2, ampliﬁcation started with DNA denat-
uration at 95˚C for 2 min, followed by 45 cycles of 95˚C for
1 min, 60˚C for 30 s, 72˚C for 1 min, and was stopped with a
ﬁnal extension step at 72˚C for 5 min. The PCR products were
subjected to electrophoresis on a 2% agarose gel stained with
ethidium bromide. The relative gel bands were analyzed using a
computerized densitometric analysis system (Quantity One 4.4.0,
Biorad, Hercules, CA, USA) and the protein/β-actin ratio was
calculated.
DRUG TRANSPORTER FUNCTIONAL ASSAYS
The functionality of some transporters (P-gp and MRP-1) was
tested by assessing the uptake of the substrate calcein-AM (spe-
ciﬁc for P-gp and MRP-1) in the absence or presence of speciﬁc
inhibitors such as verapamil for P-gp and MK-571 for MRP-1,
respectively. The assay was performed as previously described
(Hollò et al., 1994). Brieﬂy, 2× 106 brain endothelial cells/ml cul-
tured alone or in the presence of glial cells as above described,
were washed and then cultured in HPMI medium in 96-well
microplates at 37˚Cwith 0.25μMcalcein-AM(Sigma) added from
a stock solution in dimethyl sulfoxide, for 10 min in the absence or
presence of the speciﬁc inhibitors (40μM verapamil, 10μM MK-
571, respectively, all from Sigma) preincubated for 5 min. Cells
were trypsinized for 15 min, washed, then incubated with 1% Tri-
ton X-100 in HPMI for 5 min and ﬂuorescence was measured in a
Perkin Elmer LS 30 ﬂuorescence spectrophotometer with 493 nm
excitation and 515 emission wavelengths. A calibration curve of
dye concentration was performed measuring free calcein (Sigma)
ﬂuorescence at the identical conditions as calcein-AM.
STATISTICAL ANALYSIS
Comparison of the cellular ELISA assays as well as immunoblot-
ting and PCR gel band density was performed with the paired
t -test. Normal distribution of the data was tested by the
Kolmogorov–Smirnov test. p< 0.05 was considered signiﬁcant.
Statistical analysis was performed with the GraphPad Prism
version 3.0 software, San Diego, CA, USA.
RESULTS
CELL VIABILITY AND TEER ASSESSMENT
At 7 DIV, an MTT assay revealed a signiﬁcant (13%) increase
of cell viability in the presence of astroglial cells (p = 0.0077). A
very signiﬁcant (47%) increase of TEER was also detected at 7
DIV in brain endothelial cells in the presence of astroglial cells
(p< 0.0001; Figures 2A,B).
EXPRESSION OF TIGHT JUNCTION AND DRUG EFFLUX TRANSPORTER
PROTEINS
In the co-culture system with glial cells, TJ proteins (ZO-1, OCLN
and CLN-5) showed signiﬁcantly higher expression compared to
the cultures of brain endothelial cells alone, ranging from 13.3%
for OCLN (p = 0.002) to 14.3% for CLN-5 (p< 0.0001) as well as
21% for ZO-1 (p = 0.0043; Figure 3A). A signiﬁcantly increased
expression of several drug transporters (P-gp, MRP-2, oatp1) was
also observed in brain endothelial cells co-cultured with glial
cells, ranging from 9.4% for MRP-2 to 19% for P-gp (p = 0.009
and p = 0.0013, respectively); oatp1 was found to be increased
by 12.5% (p = 0.0005). In contrast, no signiﬁcant change was
observed for MRP-1 (+2.8%,p = 0.33) and oatp3 (+9%,p = 0.23,
respectively; Figure 3B).
EXPRESSION OF TIGHT JUNCTION AND DRUG EFFLUX TRANSPORTER
MRNA LEVELS
When brain endothelial cells were co-cultured with glial cells, a
signiﬁcant increase of gene transcripts was found for all TJ pro-
teins with different extent. In particular, transcripts of ZO-1 a and
b increased by 90 and 101%, p = 0.0017 and 0.0099, respectively. A
higher increase was found for OCLN and CLN-5 (124 and 168%,
p = 0.0003 and 0.0005, respectively). A wide range of increase
was found for the transcripts of drug transporter proteins. Oatp3
increased by 40% (p = 0.014) and P-gp by 48% (p = 0.0073). By
contrast, oatp1 increased by 218% (p = 0.0097), MRP-1 by 328%
(p = 0.006) and MRP-2 by 149% (p = 0.025; Figure 4).
FIGURE 2 | (A) Cell viability of human brain endothelial cells
(HUBEC) in the presence or absence of glioma cells. The results are
shown as mean±SEM of optical density (OD) values of duplicate
batches of three independent cultures (2×104 cells/well) from three
different tumors listed inTable 1 (n =3). (B)Transendothelial
electrical resistance of human brain endothelial cells (HUBEC) in the
presence or absence of glioma cells. The results are expressed as
mean±SEM of Ω cm2 of duplicate batches of three independent
cultures (2×104 cells/well) from three different tumors listed in
Table 1 (n =3).
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FIGURE 3 | (A) Expression of tight junction proteins in human brain
endothelial cell cultures (HUBEC) in the presence or absence of glioma
cells. The results are shown as mean±SEM of optical density (OD) values
of duplicate batches of three independent cultures from three different
tumors listed inTable 1 (n =3). Iso, antibody isotype; ZO-1, zonula
occludens; OCLN, occludin; CLN-5, claudin-5. ∗HUBEC vs HUBEC+
glioma, p =0.0005; ∗∗HUBEC vs HUBEC+glioma, p =0.002; °HUBEC vs
HUBEC+glioma, p<0.0001 (paired t -test). (B) Expression of drug
transporter proteins in human brain endothelial cell cultures (HUBEC) in
the presence or absence of glioma cells. The results are shown as
mean±SEM of optical density (OD) values of duplicate batches of three
independent cultures from three different tumors listed inTable 1 (n =3).
Iso, antibody isotype; P-gp, P-glycoprotein; MRP-1, multidrug resistance
protein-1; MRP-2, multidrug resistance protein-2; oatp1, organic
anion-transporting polypeptide-1; oatp3, organic anion-transporting
polypeptide-3. ∗HUBEC vs HUBEC+glioma, p =0.001; ∗∗HUBEC vs
HUBEC+glioma, p =0.009; °HUBEC vs HUBEC+glioma, p =0.0005
(paired t -test).
DRUG TRANSPORTER FUNCTIONAL ASSAYS
To test whether expressed P-gp and MRP-1 were functionally
active, we assessed the rate of calcein-AM uptake by endothelial
cells. We found that brain endothelial cells cultured alone, were
able to uptake very low amounts of calcein-AM that markedly
increased, in the presence of the speciﬁc inhibitors verapamil and
MK-571, by 178 and 167%, respectively. When brain endothelial
cells were co-culturedwith glial cells, a signiﬁcantly higher increase
of uptake of calcein-AM than that of brain endothelial cells cul-
tured alone was found (with no inhibitors by 47%, p = 0.025; in
the presence of verapamil by 681%, p = 0.01; in the presence of
MK-571 by 553%, p = 0.0075) indicating a signiﬁcantly higher
availability of functionally active P-gp and MRP-1 (Figure 5).
DISCUSSION
Our study demonstrates that an in vitro model of the human
BBB may be obtained from cryopreserved brain tumor specimens
belonging to the glial cell phenotype. In particular, brain endothe-
lial cells isolated from these tissues displayed high viability and
retained several physiological properties including the ability to
form TJs, as shown by the constitutive expression of the principal
proteins participating in their formation, such as OCLN, ZO-1,
and CLN-5, at both protein and gene transcript level. In addi-
tion, P-gp and MRP-1 were found to be functionally active. These
ﬁndings suggest that isolated vessels from glial tumors, although
displaying in situ genomic alterations similar to those found in
glioma cells (reviewed in Hjelmeland et al., 2011), are able to
express in vitro, at the culture conditions used in our model, the
physiological properties needed to establish valid monolayers to
build a BBB model. We found high viability in brain endothelial
cells obtained frombrain tumor tissues thatwere cryopreserved for
up to 3 months (data not shown). We also found a low variability
of the main parameters tested such as TEER, TJ protein expression
and functional activity of two important drug transporters such
as P-gp and MRP-1 among specimens from different glial tumors
such as astrocytomas of low and high grade of malignancy and
glioblastoma multiform. This ﬁnding demonstrates that different
glial tumors, independently of their degree of malignancy, may be
used and eventually pooled to obtain reproducible primary brain
endothelial cultures. TJs are the result of complex interactions
between several transmembrane and cytoskeletal proteins. ZO-1
is fundamental in linking other TJ proteins, such as CLNs, OCLN
and JAM-1, to the actin cytoskeleton (Farshori and Kachar, 1999;
Mitic et al., 2000). In our model, in vitro TJ formation was also
documented by the detection of reliable TEER values, suggesting
the development of a valid electrical resistance due to cell mono-
layer tightness. Furthermore, brain endothelial cells expressed a
number of transporter proteins that are involved in maintaining
brain homeostasis by selectively regulating the passage of com-
pounds across the BBB and inhibiting the delivery of drugs into
the brain parenchyma. It is therefore important to obtain in vitro
BBB models that are capable of providing adequate experimental
conditions to study the inﬂuence of transporters in pharmacolog-
ical resistance and to test the ability to enter brain parenchyma
of new drugs targeting the CNS. In the primary brain endothelial
cells co-cultured with glial cells we found a signiﬁcant increase
in the expression of TJ proteins, as well as transporter proteins
and up-regulation of their related transcripts, conﬁrming previ-
ous observations in other brain endothelial cell cultures (Cecchelli
et al., 1999). This increase differed among the individual proteins.
In particular oatp3, an organic anion transporter located mainly
at the apical and basolateral side of brain capillary endothelial cells
and at the apical side of choroid plexus (Kusahara et al., 2003) and
MRP-1 were found to be slightly changed at the protein expression
level but displayed a signiﬁcant up-regulation of their related gene
transcripts, suggesting a different post-transcriptional pathway of
regulation that remains to be elucidated. With regard to ZO-1,
we found a signiﬁcant up-regulation of both gene transcripts,
detected as result of alternative RNA splicing (Willott et al., 1992).
This ﬁnding suggests that both isoforms,expressed inhumanbrain
endothelial cells, are subjected to regulation by a putative glia-
derived factor. A signiﬁcantly high increase was also found at the
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FIGURE 4 | RT-PCR analysis of tight junction and drug transporter gene
transcripts in human brain endothelial cell cultures (HUBEC) in the
presence or absence of glioma cells. (A) Representative ethidium
bromide-stained agarose gels of the RT-PCR ampliﬁed tight junction and drug
transporter gene mRNA and β-actin gene. (a) Lane 1: DNA ladder markers;
lane 2: negative control obtained omitting reverse transcriptase from the RT
mixture; lane 3: ZO-1a and ZO-1b in the absence of glioma cells; lane 4: ZO-1a
and ZO-1b in the presence of glioma cells; lane 5: OCLN in the absence of
glioma cells; lane 6: OCLN in the presence of glioma cells; lane 7: CLN-5 in
the absence of glioma cells; lane 8: CLN-5 in the presence of glioma cells. (b)
Lane 1: DNA ladder markers; lane 2: negative control; lane 3: MRP-2 in the
absence of glioma cells; lane 4: MRP-2 in the presence of glioma cells; lane 5:
MRP-1 in the absence of glioma cells; lane 6: MRP-1 in the presence of
glioma cells; lane 7: P-gp in the absence of glioma cells; lane 8: P-gp in the
presence of glioma cells. (c) Lane 1: DNA ladder markers; lane 2: negative
control; lane 3: oatp1 in the absence of glioma cells; lane 4: oatp1 in the
presence of glioma cells; lane 5: oatp3 in the absence of glioma cells; lane 6:
oatp3 in the presence of glioma cells; lane 7–8: negative control. (d) Lane 1:
DNA ladder markers; lane 2: negative control; lane 3–8: β-actin gene. On the
left, base pair (bp) size of the DNA ladder markers, on the right, bp size of the
gene products. (B) Expression ratios of tight junction mRNA obtained dividing
tight junction mRNA densitometric values by those of β-actin. The results are
expressed as mean±SEM of three independent cultures in the presence or
absence of glioma cells from three different tumors listed inTable 1 (n =3).
∗HUBEC vs HUBEC+glioma, p =0.0017; ∗∗HUBEC vs HUBEC+glioma,
p =0.009; °HUBEC vs HUBEC+glioma, p=0.0003; °°HUBEC vs
HUBEC+glioma, p =0.0005 (paired t -test). (C) Expression ratios of drug
transporter mRNA obtained dividing drug transporter mRNA densitometric
values by those of β-actin. The results are expressed as mean±SEM of three
independent cultures in the presence or absence of glioma cells from three
different tumors listed inTable 1 (n =3). ∗HUBEC vs HUBEC+glioma,
p =0.006; ∗∗HUBEC vs HUBEC+glioma, p =0.025; °HUBEC vs
HUBEC+glioma, p =0.0097; °°HUBEC vs HUBEC+glioma, p =0.014;
§HUBEC vs HUBEC+glioma, p =0.0073 (paired t -test). ZO-1, zonula
occludens; OCLN, occludin; CLN-5, claudin-5; P-gp, P-glycoprotein; MRP-1,
multidrug resistance protein-1; MRP-2, multidrug resistance protein-2; oatp1,
organic anion-transporting polypeptide-1; oatp3, organic anion-transporting
polypeptide-3.
both protein and gene transcript level for CLN-5, a member of
the claudin family mainly detected in brain endothelial cells at the
TJs (Morita et al., 1999) and found to be decreased in a murine
cerebral endothelial line exposed to sera of patients with multiple
sclerosis on clinical relapse (Blecharz et al., 2010).
The role of glia in the differentiation and induction of func-
tional properties in the brain endothelium is well known and
probably depends on cell–cell contact, as well as on soluble factors
secreted by glial cells, some of which have been identiﬁed or are
thought to play a role in this activity such as cyclic AMP (Beuck-
mann et al., 1995). However, the nature of other possible soluble
factors is unknown and remains to be elucidated. Our model dif-
fers from other co-culture systems due to the presence of glial
cells derived from the same brain tissue specimen that the brain
endothelial cells were isolated from, growing in the same feed-
ing medium as that of the brain endothelial cells, although not
in close contact (as in other culture systems in which glial cell
lines were grown on the opposite side of ﬁlter membranes con-
taining immortalized human brain endothelial cell lines; Megard
et al., 2002). The central role of astrocytes in inducing physiolog-
ical properties in human brain endothelial cells to establish BBB
monolayers was further highlighted in an in vitro BBB model by
co-culturing commercially available human brain endothelial cells
with human astrocytes making cell–cell contact via a porous syn-
thetic membrane (Kuo and Lu, 2011). The ﬁndings of our model
are consistent with those of another recent study demonstrating
that human brain endothelial cells derived from a cell line and
co-cultured, with no cell–cell contact, with human fetal astrocytes
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FIGURE 5 | Calcein uptake by brain endothelial cultures in the
presence or absence of P-gp and MRP-1 inhibitors (verapamil and
MK-571, respectively).The results are expressed as mean±SEM of
duplicate batches of three independent cultures in the presence or absence
of glioma cells from three different tumors listed inTable 1 (n =3).
Calcein-AM, brain endothelial cultures exposed to calcein-AM; Verapamil,
brain endothelial cultures preincubated with verapamil; MK-571, brain
endothelial cultures preincubated with MK-571; HUBEC, human brain
endothelial cells; HUBEC+glioma, human brain endothelial cells in the
presence of glioma cells. ∗HUBEC vs HUBEC+glioma, p =0.025;
∗∗HUBEC vs HUBEC+glioma, p =0.01; °HUBEC vs HUBEC+glioma,
p =0.0075 (paired t -test).
showed increased TEER values and higher expression of ZO-1
(Siddharthan et al., 2007). The lack of cell–cell contact, though
different from the real BBB structure, may however allow to study
and attempt to isolate eventual soluble glia-derived growth factors
acting on the brain endothelial cells by comparing the ﬁndings
obtained in brain endothelial cultures alone and in the presence
of glial cells. It also provides a tool for the study of native brain
endothelium surface molecules involved in cell trafﬁcking and the
passage of compounds across theBBB, thus overcoming the species
differences present in other culture systems using non-human
nervous tissues.
Recently, two human BBB models have been described, one
based on commercially available human brain endothelial cells co-
cultured with astroglial cells derived from adult normal human
cerebral tissue (Megard et al., 2002). This model was found
suitable to test passage of indinavir, a known anti-HIV-1 pro-
tease inhibitor. The other one was an incomplete model based
on use of an immortalized human brain endothelial cell line
with lentivirus infection but without astroglial cell contact (Wek-
sler et al., 2005). Our model represents an additional complete
BBB model displaying all characteristics suitable to study even-
tual changes of TJ proteins as well drug transporters exposed
to biological ﬂuids or supernatants of immunocompetent cells
derived from patients with several neurological disorders. The
main advantage of our proposed model is the cryopreservation
of the nervous tissue used for preparing primary endothelial cell
cultures. This allows to obtain sufﬁcient amount of specimens
that could be pooled later and provide a large number of pri-
mary brain endothelial cells circumventing the known obstacle to
expand in vitro endothelial cells derived from human adult brain
tissue.
Alterations in BBB functionality and permeability have been
shown in several immune-mediated or infectious and degenera-
tive neurological diseases, such as multiple sclerosis (Minagar and
Alexander, 2003), HIV-related neurological disorders (reviewed
in Annunziata, 2003) and Alzheimer’s disease (Bell and Zlokovic,
2009). Our primary brain endothelium culture system, which
mimics a physiologically relevant situation, may therefore pro-
vide a new tool for studying the effects of biological ﬂuids such
as serum and cerebrospinal ﬂuid from patients with neurological
disorders underlying a BBB alteration in disease pathogenesis.
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